Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644498 · ClinicalTrials.gov registry record
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,056
- Enrollment target
NCT03644498: Completed study, sponsored by Bristol-Myers Squibb.
NCT03644498 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,056 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03644498 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,056 participants
- Enrollment target
Study Summary
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2018-10-17 |
What the finished NCT03644498 record still lists
NCT03644498 is an observational study that tracks outcomes without assigning an intervention. Its 1,056 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03644498 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03644498 about?
NCT03644498 is a clinical study titled "Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells". A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
What is the current status of trial NCT03644498?
This trial is currently completed. The enrollment target is 1,056 participants. The study started on 2018-05-02. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03644498?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03644498?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03242642 · 1,056 participants · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI